Last reviewed · How we verify

NCT04322201: COPPTRIAHL

Continuous Passive Paracentesis for Intra-abdominal Hypertension

Status unknown NA Last updated 26 March 2020
What this trial tests

NA trial testing continuous drainage of ascitic fluid using an intra-abdominal double lumen central venous catheter in Ascites Hepatic in 60 participants. Status unknown.

Timeline
2 November 2019
Primary endpoint
30 November 2021
31 May 2022

Quick facts

Lead sponsorCentro Hospitalar de Lisboa Central
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment60
Start date2 November 2019
Primary completion30 November 2021
Estimated completion31 May 2022
Sites1 location across Portugal

Drugs / interventions tested

Conditions studied

Sponsor

Centro Hospitalar de Lisboa Central

Who can join

Adults 18 to 75, any sex, with Ascites Hepatic or Cirrhosis, Liver. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Liver cirrhosis patients in Intensive Care present intra-abdominal hypertension and this is an independent risk factor for increased organ disfunction and mortality. Patients will be randomized into intermittent or continuous passive paracentesis and the clinical results of these two strategies for preventing and treating intra-abdominal hypertension will compared.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Intra-abdominal hypertension and abdominal compartment syndrome in the critically ill liver cirrhotic patient-prevalence and clinical outcomes. A multicentric retrospective cohort study in intensive care.
    Pereira R, Buglevski M, Perdigoto R, Marcelino P, et al · · 2021 · cited 17× · PMID 33984016 · DOI 10.1371/journal.pone.0251498
  2. Continuous passive paracentesis versus large-volume paracentesis in the prevention and treatment of intra-abdominal hypertension in the critically ill cirrhotic patient with ascites (COPPTRIAHL): study protocol for a randomized controlled trial.
    Pereira RA, Virella D, Perdigoto R, Marcelino P, et al · · 2023 · cited 1× · PMID 37582719 · DOI 10.1186/s13063-023-07541-4
  3. ESICM LIVES 2025
    · 2025

Verify or expand the search:

Other recruiting trials for Ascites Hepatic

Currently open trials in the same condition.

Other Centro Hospitalar de Lisboa Central trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04322201.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing